Saturday, January 9, 2016

The Effects of Transdermal Dihydrotestosterone on Patients with Micropenis Condition

In the past, I have shared on the site two studies showing how instra-muscular testosterone injections can induce significant penile gains in young patients presenting with the micropenis condition. If you have missed them you can click here and here to learn more about testosterone therapy.

A reader of the site brought to my attention another very interesting study named "Transdermal dihydrotestosterone therapy and its effects on patients with microphallus".  The study was published in 1993 and what I find very interesting is that the treatment protocol involved no injections, no oral administration of drugs, no surgery, no use of penile extenders, no nothing. Just the topical application of a Transdermal dihydrotestosterone cream on the genitals, for 8 weeks.

Considering the simplicity of the method, the reported results are mind blowing:

"All patients demonstrated growth of the penis during treatment. The mean increase rate (153%) in the first 4 weeks of treatment was higher than that (118%) of the second 4 weeks."

What is even more surprising is that the treatment was a success in patients were intramuscular testosterone had previously failed:

"Of importance is that responses were noted in 4 patients who had failed testosterone therapy for microphallus."

Here's is the full abstract of the study:

"To investigate the efficacy of transdermal dihydrotestosterone therapy on 22 patients with microphallus, we applied dihydrotestosterone gel for 8 weeks to the external genitalia at daily doses of 12.5 mg. and 25 mg. for ages less than and older than 10 years, respectively. All patients were evaluated for penile and prostatic growth, pituitary-gonadal axis function, serum sex hormone binding globulin, lipid metabolism, hepatotoxicity, bone age and height velocity. All patients demonstrated growth of the penis during treatment. The mean increase rate (153%) in the first 4 weeks of treatment was higher than that (118%) of the second 4 weeks. Of importance is that responses were noted in 4 patients who had failed testosterone therapy for microphallus. The pituitary-gonadal axis was transiently suppressed during treatment, and serum sex hormone binding globulin and lipid metabolism were transiently affected during treatment. Serum alkaline phosphatase increased, mainly due to change of bone isoenzyme but bone ages and mean height velocity were not significantly affected. In conclusion, transdermal dihydrotestosterone therapy is an effective and relatively safe modality in the treatment of microphallus."


What is  Dihydro-testosterone? 
Dihydrotestosterone (DHT), or 5α-dihydrotestosterone (5α-DHT), also known as 5α-androstan-17β-ol-3-one, is a sex steroid and androgen hormone. Also known as androstanolone (INN) and stanolone (BAN). Some common brand names include Anabolex, Anaprotin, Andractim, Androlone, Gelovit, Neoprol, Pesomax, and Stanaprol.

DHT is used clinically as an androgen and anabolic steroid. In the human body, it is synthesized from testosterone (with the help of the 5α-reductase enzyme) in the prostate, testes, hair follicles, and adrenal glands. Compared to testosterone, DHT is much more potent as an agonist of the androgen receptor.

diagram showing the structure of Dihydrotestosterone
Structural diagram of dihydrotestosterone


References
- Choi SK, Han SW, Kim DH, & de Lignieres B. (1993) Transdermal dihydrotestosterone therapy and its effects on patients with microphallus. The Journal of urology, 150(2 Pt 2), 657-60.

No comments:

Post a Comment

The comments are moderated. It usually takes 1-2 hours until they get approved.